<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799615</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0063; 2015-8753</org_study_id>
    <nct_id>NCT02799615</nct_id>
  </id_info>
  <brief_title>Anti-TNF Therapy for Refractory Colitis in Hospitalized Children</brief_title>
  <acronym>ARCH</acronym>
  <official_title>Multicenter Non-Therapeutic Study of Infliximab for Severe Refractory Colitis in Hospitalized Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Crohn's and Colitis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter study is being conducted to determine whether infliximab exposure after an&#xD;
      initial infusion is predictive of early clinical response in hospitalized pediatric patients&#xD;
      with severe steroid-refractory UC or IBD-U. This pilot and feasibility study will establish&#xD;
      the infrastructure, demonstrate feasibility, and collect preliminary data to support the full&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter prospective non-interventional cohort study to identify clinical and&#xD;
      biological markers that predict non-response in hospitalized pediatric patients with severe&#xD;
      corticosteroid-refractory UC or inflammatory bowel disease unspecified (IBD-U) being&#xD;
      initiated on infliximab.&#xD;
&#xD;
      Patients hospitalized with severe UC or IBD-U (PUCAI ≥ 65 on admission) and failing&#xD;
      intravenous corticosteroids will be eligible. Blood, stool, and rectal biopsies (if&#xD;
      sigmoidoscopy performed for clinical indications) will be collected for translational studies&#xD;
      (Aim 3). Patients will receive infliximab per the dose and regimen determined by clinical&#xD;
      physician. No standard dosing regimen will be used and the dose of IFX will be determined by&#xD;
      the treating physician. Serial PUCAI scores and infliximab levels will be obtained.&#xD;
&#xD;
      Those who are eligible to participate will have serial blood samples taken in association&#xD;
      with drug infusions to perform pharmacokinetic/pharmacodynamic modeling of infliximab&#xD;
      exposure. Clinical response will be determined using the Pediatric UC Activity Index (PUCAI)&#xD;
      questionnaire.&#xD;
&#xD;
      Initially, 6 centers will participate with a minimum target enrollment goal of 36 evaluable&#xD;
      pediatric research participants (to a maximum of 40) age &gt; 4 years or &lt; 18 years old with UC&#xD;
      or IBD-U (average 6/center).&#xD;
&#xD;
      The primary endpoint will be the relationship between IFX exposure (area under the curve of&#xD;
      the PK model) and Day 7 clinical response defined as Pediatric Ulcerative Colitis Activity&#xD;
      Index (PUCAI) ≤ 35. Secondary endpoints will be Week 8 clinical remission, and Week 26&#xD;
      steroid-free, colectomy-free remission. We will initially enlist 6 centers, and enroll 36-40&#xD;
      evaluable patients in 2 years.&#xD;
&#xD;
      This study described by this protocol is designed as pilot and feasibility study, which we&#xD;
      anticipate will ultimately be expanded to larger study. Therefore, to demonstrate feasibility&#xD;
      and begin the development of a biorepository on this patient population, certain biospecimens&#xD;
      will be collected for this study and anticipated future translational studies as follows:&#xD;
&#xD;
        -  Blood will be used for IFX pharmacokinetic assays (e.g. levels, antibodies) and future&#xD;
           biomarker discovery.&#xD;
&#xD;
        -  Blood DNA we anticipate will be used for genotype/phenotype correlations and genetic&#xD;
           predictors of rapid infliximab clearance and non-response.&#xD;
&#xD;
        -  Colon tissue RNA will be used for determining how local gene expression patterns predict&#xD;
           or explain infliximab clearance or non-response.&#xD;
&#xD;
        -  Colon tissue DNA we anticipate will be used for studies of how the microbiome or&#xD;
           epigenetic changes relate to severe UC or response to infliximab.&#xD;
&#xD;
        -  Colon tissue will be used for determining the relationship between tissue TNF levels (or&#xD;
           other proteins) and infliximab clearance or non-response.&#xD;
&#xD;
        -  Stool will be collected for serial measurement of fecal calprotectin and future&#xD;
           microbiome studies&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">November 2019</completion_date>
  <primary_completion_date type="Actual">February 11, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint will be the relationship between IFX exposure (area under the curve of the PK model) and Day 7 clinical response defined as Pediatric Ulcerative Colitis Activity Index (PUCAI) &lt;35.</measure>
    <time_frame>7 days</time_frame>
    <description>IFX exposure and Day 7 PUCAI</description>
  </primary_outcome>
  <enrollment type="Actual">38</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <condition>Bowel Diseases, Inflammatory</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>No standard dosing regimen will be used and the dose of infliximab will be determined by the treating physician</description>
    <other_name>Remicade</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, blood DNA, serum, plasma, colon endoscopic biopsy tissue (RNA/DNA/Formalin-fixed),&#xD;
      stool (DNA and supernatant)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Research participants age 4 to 17 will be eligible for this study. Our target is a minimum&#xD;
        of 36 evaluable research participants (to a maximum of 40) across up to 6 participating&#xD;
        centers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age criteria: ≥ 4 or &lt; 18 years of age&#xD;
&#xD;
          2. Diagnosis of UC or IBD-U by established criteria&#xD;
&#xD;
          3. Admitted to the hospital&#xD;
&#xD;
          4. Colitis extending beyond the rectosigmoid colon&#xD;
&#xD;
          5. PUCAI ≥ 65 at admission and ≥ 45 at first dose of infliximab&#xD;
&#xD;
          6. Treatment with infliximab considered by the treating physician&#xD;
&#xD;
          7. Anticipated follow-up ≥ 6 months from infliximab initiation&#xD;
&#xD;
          8. Permission/assent of parent/guardian and research participant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Crohn's disease&#xD;
&#xD;
          2. Enteric infection with a bacterial pathogen (including clostridium difficile), per&#xD;
             review of medical records&#xD;
&#xD;
          3. Colon tissue positive for CMV by PCR, immunohistochemistry, or in situ hybridization,&#xD;
             per review of the medical records&#xD;
&#xD;
          4. Colitis currently extending only to the rectosigmoid colon (proctosigmoiditis)&#xD;
&#xD;
          5. Prior treatment with infliximab or other anti-TNF agent&#xD;
&#xD;
          6. Prior treatment with cyclosporine or tacrolimus&#xD;
&#xD;
          7. PUCAI &lt; 45 the day of first infliximab infusion&#xD;
&#xD;
          8. Pregnancy, per review of medical records and verbal report&#xD;
&#xD;
          9. Other poorly controlled medical condition&#xD;
&#xD;
         10. Hepatic disease (AST or Alk Phos &gt; 3 times the upper limit of normal) in the absence&#xD;
             of IBD associated liver disease&#xD;
&#xD;
         11. Renal disease (BUN and creatinine &gt;1.5 times the upper limit of normal)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Rosen, MD, MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Connecticut Children's Hospital Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

